Payment overview · 2025
General Payments
$49.68
3 reported records · 3 companies
Healthcare provider profile · identity verified
Seema Bery, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MORRISTOWN, NJ · NPI 1871526632
Verified facts
What the public records show
CMS Open Payments records show Seema Bery, M.D. received $49.68 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 272 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.34 | 38.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.61 | 31.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.73 | 29.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.68 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 272 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
272 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 486 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 445 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 352 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 328 | 76 |
| Eliquis | Apixaban | 272 | 42 |
| Gabapentin | Gabapentin | 235 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 217 | 46 |
| Losartan Potassium | Losartan Potassium | 215 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 38 |
| Sertraline Hcl | Sertraline Hcl | 177 | 39 |
| Furosemide | Furosemide | 176 | 42 |
| Donepezil Hcl | Donepezil Hcl | 162 | 46 |
| Divalproex Sodium | Divalproex Sodium | 153 | 31 |
| Mirtazapine | Mirtazapine | 137 | 30 |
| Metformin Hcl | Metformin Hcl | 128 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 24 |
| Memantine Hcl | Memantine Hcl | 120 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 24 |
| Famotidine | Famotidine | 95 | 19 |
| Januvia | Sitagliptin Phosphate | 93 | 15 |
| Carvedilol | Carvedilol | 84 | 17 |
| Trazodone Hcl | Trazodone Hcl | 82 | 21 |
| Buspirone Hcl | Buspirone Hcl | 79 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 22 |
| Lisinopril | Lisinopril | 78 | 19 |
| Simvastatin | Simvastatin | 78 | 17 |
| Finasteride | Finasteride | 77 | 12 |
| Allopurinol | Allopurinol | 73 | 15 |
| Spironolactone | Spironolactone | 73 | 18 |
| Jardiance | Empagliflozin | 67 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 65 | 17 |
| Omeprazole | Omeprazole | 61 | 14 |
| Torsemide | Torsemide | 59 | 16 |
| Valsartan | Valsartan | 59 | 12 |
| Bupropion Xl | Bupropion Hcl | 57 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 49 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 14 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Risperidone | Risperidone | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Prednisone | Prednisone | 40 | 12 |
| Topiramate | Topiramate | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Budesonide | Budesonide | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 13 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Alprazolam | Alprazolam | 27 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Teriflunomide | Teriflunomide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Latanoprost | Latanoprost | 23 | suppressed |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lamivudine | Lamivudine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Tivicay | Dolutegravir Sodium | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Dalfampridine Er | Dalfampridine | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Primidone | Primidone | 15 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.68 · 3 records | Otsuka America Pharmaceutical, Inc. | ELIQUIS, KISUNLA, NURTEC ODT, REXULTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error